Person: TURGUT, SEDA
Search Results
Does DRD2 polymorphism influence the clinical characteristics of prolactinoma?
2015-10-01, Ilhan, MAHMUT MUZAFFER, Kahraman, Ozlem Timirci, Turan, Saime, Turgut, SEDA, Karaman, Ozcan, Zeybek, Umit, SHUKUROV, Samir, Yaylim, Ilhan, Tasan, ERTUĞRUL, İLHAN, MAHMUT MUZAFFER, TURGUT, SEDA, KARAMAN, ÖZCAN, TAŞAN, ERTUĞRUL
Objectives. - Genetic alterations explaining the clinical variability of prolactinomas still could not be clarified and dopamine D2 receptor (DRD2) polymorphism is a putative candidate for the variable response to dopaminergic treatment. The present study was conducted to investigate the influence of DRD2 TaqI A polymorphism on initial and follow-up characteristics of prolactinoma. Patients and methods. - Seventy-two patients with prolactinoma and 98 age and gender matched control subjects were recruited to the case-control study. Serum prolactin levels were assessed by enzyme-linked immunosorbent assay and DRD2 polymorphism was determined by polymerase chain reaction and restriction length polymorphism analysis. Results. - Decrease of prolactin levels and the tumor shrinkage after cabergoline treatment were 93.9 +/- 5.9% and 58.3 +/- 33.1% in microadenomas and 96.1 +/- 6.1% and 51.7 +/- 29.3 in macroadenomas (P = 0.02 and P > 0.05, respectively). We observed no significant difference for DRD2 genotypes and the alleles between the patients and healthy group (P > 0.05). Prolactin levels before treatment were correlated with tumor diameter before and after treatment and the percentage of prolactin decrease with treatment (P 0.05). Conclusion. - This study revealed that DRD2 TaqI A receptor polymorphism was not associated with the development of prolactinoma and its clinical characteristics. Future studies are needed to clarify the clinical implications of genetic alterations in prolactinoma. (C) 2015 Elsevier Masson SAS. All rights reserved.
Rapid improvement in visual loss with cabergoline treatment in a giant prolactinoma case: 5 years survey
2015-01-01T00:00:00Z, Tasan, ERTUĞRUL, HANIMOGLU, Hakan, Turgut, SEDA, Ilhan, MAHMUT MUZAFFER, EVRAN, Sevket, KAYNAR, Mehmet Yasar, TAŞAN, ERTUĞRUL, TURGUT, SEDA, İLHAN, MAHMUT MUZAFFER
Giant prolactinoma is a rare subset of macroadenomas. Limited studies demonstrated which therapy could be successfully used in the first-line therapy of giant prolactinoma. We presented a case with a 54x40x40 mm pituitary adenoma and optic chiasmatic compression with left sphenoid sinus invasion. The tumor caused a loss of visual field of the right side. Cabergoline treatment was started with dose of 1.5 mg/week. Fifteen days later, the clinical visual acuity examination showed a significant improvement in the patient with visual field defect. After the five years follow-up magnetic resonance imagining showed reduction of the adenoma size (17x12 mm) was significant. Our findings suggest that, cabergoline can be used as a first-line therapy in giant prolactinomas because tumoral shrinkage without a surgical procedure and rapid improvement in visual field defect is achieved with this medical treatment.
Esophagus motility in overt hypothyroidism
2014-07-01, Ilhan, MAHMUT MUZAFFER, Arabaci, ELİF, Turgut, SEDA, Karaman, Ozcan, DANALIOGLU, Ahmet, Tasan, ERTUĞRUL, İLHAN, MAHMUT MUZAFFER, ARABACI, ELİF, TURGUT, SEDA, KARAMAN, ÖZCAN, TAŞAN, ERTUĞRUL
Purpose Gastrointestinal tract is one of the most affected systems in hypothyroidism. Despite decreased esophageal emptying, prolonged esophageal and gastric transit time have been indicated in previous reports, the mechanism of thyroid hormones activity and antibodies on the esophagus motility is not yet fully understood. This study was conducted to evaluate the esophagus motility by manometry in hypothyroid patients.
Preoperative therapeutic plasma exchange for severe hyperthyroidism in a patient with peptic ulcer perforation
2014-10-15, TURGUT, SEDA, ÖZKAN, TUBA, ISMAYILOVA, MEDINA, CENGİZ, MERVE, İLHAN, MAHMUT MUZAFFER, ÇETİN, GÜVEN, TURGUT, SEDA, İLHAN, MAHMUT MUZAFFER, ÇETİN, GÜVEN
A novel AVP gene mutation in a Turkish family with neurohypophyseal diabetes insipidus
2016-03-01, Ilhan, MAHMUT MUZAFFER, Tiryakioglu, N. O., KARAMAN, O., Coskunpinar, E., YILDIZ, R. S., TURGUT, SEDA, Tiryakioglu, D., TOPRAK, HÜSEYİN, TASAN, ERTUĞRUL, İLHAN, MAHMUT MUZAFFER, KARAMAN, ÖZCAN, TURGUT, SEDA, TOPRAK, HÜSEYİN, TAŞAN, ERTUĞRUL
Purpose Familial neurohypophyseal diabetes insipidus (FNDI) is a rare, autosomal dominant, inherited disorder which is characterized by severe polydipsia and polyuria generally presenting in early childhood. In the present study, we aimed to analyze the AVP gene in a Turkish family with FNDI.
DO WE REALLY TREAT ESSENTIAL THROMBOCYTHEMIA? A CLINICAL TRIAL OF 148 PATIENTS WITH ET
2014-10-01, ÇETİN, GÜVEN, Ozkan, T., TURGUT, SEDA, Cevirme, N., Hamdard, J., Ayer, M., Ekinci, S., DAE, SHUTE AILIA, Ismayilova, M., Gultepe, I., Cikrikcioglu, M., ÇETİN, GÜVEN, TURGUT, SEDA, ÇEVİRME, NİDAL, DAE, SHUTE AıLıA, ISMAYILOVA, MADINA
Primer hiperparatiroidi cerrahisi sonrası osteoporozda dramatik düzelme
2014-03-15, İLHAN, MAHMUT MUZAFFER, KARAMAN, ÖZCAN, BAĞ SOYTAŞ, RABİA, TURGUT, SEDA, BÜYÜKKABA, MİTAT, TAŞAN, ERTUĞRUL, İLHAN, MAHMUT MUZAFFER, KARAMAN, ÖZCAN, TURGUT, SEDA, TAŞAN, ERTUĞRUL
Evaluation of clinical and laboratory findings with JAK2 V617F mutation as an independent variable in essential thrombocytosis.
2014-10-01, Cetin, GÜVEN, OZKAN, T, TURGUT, SEDA, Ali, Cikrikcioglu, CEM, AR M, AYER, M, UNLU, A, KARATOPRAK, CUMALİ, SEKIN, Y, ÇETİN, GÜVEN, TURGUT, SEDA, ÇELİK, ŞENGÜL, KARATOPRAK, CUMALİ
Parathyroid Carcinoma Case Report: Rapid Control of Refractory Hypercalcemia with Denosumab
2017-01-01, İLHAN, MAHMUT MUZAFFER, EKİNCİ, İSKENDER, KARAMAN, ÖZCAN, TURGUT, SEDA, TAŞAN, ERTUĞRUL, İLHAN, MAHMUT MUZAFFER, KARAMAN, ÖZCAN, TURGUT, SEDA, TAŞAN, ERTUĞRUL
Treatment modalities of non-Hodgkin lymphoma patients over 65 years of age: A two-center experience.
2019-03-29, Cetin, G, Ece, Dogan, Samanci, NS, Ayer, M, Ozkan, T, Ekinci, I, Bag, R, Uysal, O, TURGUT, SEDA, UYSAL, ÖMER